Trial · NCT01212822
Adverse events74
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 74
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Bevacizumab, FOLFOX) | 16 | 20 | |
| other | Neutrophil count decreased | Investigations | Treatment (Bevacizumab, FOLFOX) | 10 | 20 | |
| other | Platelet count decreased | Investigations | Treatment (Bevacizumab, FOLFOX) | 10 | 20 | |
| other | White blood cell decreased | Investigations | Treatment (Bevacizumab, FOLFOX) | 10 | 20 | |
| other | Fatigue | General disorders | Treatment (Bevacizumab, FOLFOX) | 17 | 20 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (Bevacizumab, FOLFOX) | 17 | 20 | |
| other | Nausea | Gastrointestinal disorders | Treatment (Bevacizumab, FOLFOX) | 10 | 20 | |
| other | Neuropathy/paresthesia | Nervous system disorders | Treatment (Bevacizumab, FOLFOX) | 13 | 20 | |
| other | Pain | General disorders | Treatment (Bevacizumab, FOLFOX) | 13 | 20 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Bevacizumab, FOLFOX) | 12 | 20 | |
| other | Weight loss | Metabolism and nutrition disorders | Treatment (Bevacizumab, FOLFOX) | 11 | 20 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Bevacizumab, FOLFOX) | 9 | 20 | |
| other | Dysphagia | Gastrointestinal disorders | Treatment (Bevacizumab, FOLFOX) | 8 | 20 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Bevacizumab, FOLFOX) | 7 | 20 | |
| other | Hypokalemia | Metabolism and nutrition disorders | Treatment (Bevacizumab, FOLFOX) | 6 | 20 | |
| other | Vomitting | Gastrointestinal disorders | Treatment (Bevacizumab, FOLFOX) | 5 | 20 | |
| other | Hypertension | Vascular disorders | Treatment (Bevacizumab, FOLFOX) | 5 | 20 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Bevacizumab, FOLFOX) | 4 | 20 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Bevacizumab, FOLFOX) | 4 | 20 | |
| other | Dysguesia | Nervous system disorders | Treatment (Bevacizumab, FOLFOX) | 4 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01212822/events